Premium
Role of TDM‐based dose adjustments for taxane anticancer drugs
Author(s) -
Muth Marsilla,
Ojara Francis Williams,
Kloft Charlotte,
Joerger Markus
Publication year - 2021
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/bcp.14678
Subject(s) - cabazitaxel , taxane , docetaxel , paclitaxel , pharmacology , medicine , pharmacokinetics , dosing , pharmacodynamics , oncology , cancer , prostate cancer , breast cancer , androgen deprivation therapy
The classical taxanes (paclitaxel, docetaxel), the newer taxane cabazitaxel and the nanoparticle‐bound nab‐paclitaxel are among the most widely used anticancer drugs. Still, the optimal use and the value of pharmacological personalization of the taxanes is still controversial. We give an overview on the pharmacological properties of the taxanes, including metabolism, pharmacokinetics‐pharmacodynamic relations and aspects in the clinical use of taxanes. The latter includes the ongoing debate on the most effective and safe regimen, the recommended initial dose, and pharmacological dosing individualization. The taxanes are among the most widely used anticancer drugs in patients with solid malignancies. Despite their longtime use in clinical routine, the optimal dosing strategy (weekly versus 3‐weekly) or optimal average dose (cabazitaxel, nab‐paclitaxel) has not been fully resolved, as it may differ according to tumour entity and line of treatment. The value of pharmacological individualization of the taxanes (TDM, TCI) has been partly explored for 3‐weekly paclitaxel and docetaxel, but remains mostly unexplored for cabazitaxel and nab‐paclitaxel at present.